GlassScriptPhysician profile
Amanda L Birkofer
NPI 1649834847
$1,987.77
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $143 · 2023: $1,669 · 2024: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $754.55 | 2023-2024 | |
| Novo Nordisk INC | $225.83 | 2022-2023 | Wegovy, Saxenda, Ozempic |
| Astrazeneca Pharmaceuticals LP | $166.07 | 2022-2023 | Breztri, Farxiga |
| Idorsia Pharmaceuticals US INC | $157.23 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $151.45 | 2023 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $127.22 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Almatica Pharma LLC | $109.11 | 2022-2023 | Gralise |
| Axsome Therapeutics, INC. | $49.71 | 2023 | Auvelity |
| Pfizer INC. | $48.84 | 2023 | |
| Abbott Laboratories | $41.18 | 2023 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $22.02 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $21.34 | 2022 | |
| Gilead Sciences, INC. | $21.17 | 2023 | |
| Mycovia Pharmaceuticals, INC. | $18.09 | 2023 | Vivjoa |
| Exact Sciences Corporation | $16.38 | 2023 | Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $15.39 | 2023 | Gvoke Hypopen |
| Corium, LLC | $14.74 | 2023 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $14.30 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.15 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Birkofer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.